Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceVideos

Study shows the importance of vaccination for myeloma patients

Influenza (i.e. “flu”) and pneumococcal vaccinations positively impact the outcomes of myeloma patients. This is the central conclusion in the article Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma (MM) Patients: Influenza and Pneumococcal Vaccination in MM, published in Clinical Lymphoma, Myeloma and Leukaemia. The article outlines an analysis of data…

Read more

ASH 2022 | Myeloma and AL amyloidosis updates

Myeloma Patients Europe (MPE) is attending the 64th American Society of Hematology (ASH) Annual Meeting, the biggest haematology congress, held from 9 to 13 December in New Orleans (United States). MPE has interviewed haematology experts to summarise the latest updates on myeloma and AL amyloidosis:

Read more

Meet Lise-Lott Eriksson, president of Myeloma Patients Europe (MPE)

Since 2015 Lise-Lott has been Chairman of the Swedish Blood Cancer Association, previously Chairman of the Blood Cancer Society in Stockholm and now the president of Myeloma Patients Europe (MPE). Lise-Lott is very active in policy-related issues within the Swedish cancer care area. She focuses on access to new drugs for haematological disorders (especially myeloma),…

Read more

EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myeloma

The European Medicines Agency (EMA) has recommended a conditional marketing authorisation in the European Union (EU) for teclistamab for the treatment of adult patients with relapsed and refractory myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose cancer has worsened since receiving the last treatment. Teclistamab, alternatively known…

Read more

Access to generic lenalidomide (e.g. Revlimid) in Europe

Sandoz, a manufacturer of generic medicines, announced the launch of generic lenalidomide in 19 European countries. You can see the full press statement here.    Alternatively known under the branded name “Revlimid”, lenalidomide is a drug licensed and commonly used in the treatment of myeloma – in newly diagnosed, maintenance and relapsed settings.   Lenalidomide…

Read more
July

August 2026

September
MO
TU
WE
TH
FR
SA
SU
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
6
Events for 1st August
No Events
Events for 2nd August
No Events
Events for 3rd August
No Events
Events for 4th August
No Events
Events for 5th August
No Events
Events for 6th August
No Events
Events for 7th August
No Events
Events for 8th August
No Events
Events for 9th August
No Events
Events for 10th August
No Events
Events for 11th August
No Events
Events for 12th August
No Events
Events for 13th August
No Events
Events for 14th August
No Events
Events for 15th August
No Events
Events for 16th August
No Events
Events for 17th August
No Events
Events for 18th August
No Events
Events for 19th August
No Events
Events for 20th August
No Events
Events for 21st August
No Events
Events for 22nd August
No Events
Events for 23rd August
No Events
Events for 24th August
No Events
Events for 25th August
No Events
Events for 26th August
No Events
Events for 27th August
No Events
Events for 28th August
No Events
Events for 29th August
No Events
Events for 30th August
No Events
Events for 31st August
No Events